Drug intelligence / Profile preview

YKR0056

Development stage: Preclinical
Lead developer: Beijing Yingkerei Pharmaceutical Technology
Modality: Small Molecules

Overview

YKR0056 is a small molecule drug candidate currently in preclinical development by Beijing Yingkerei Pharmaceutical Technology. While specific details regarding its molecular target and primary indication are not publicly disclosed in the company's high-level pipeline summaries, it is part of Beijing Yingkerei's portfolio of innovative chemical entities. The company specializes in various delivery platforms, including nebulization and traditional Chinese medicine modernization, though YKR0056 is classified specifically as a small molecule therapeutic.

Beyond the preview

Go deeper on YKR0056.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YKR0056.

Explore the full profile